Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Cancer Cell

Hailemichael et al. find that expression of interleukin-6, a Th17-cell differentiation cytokine, and neutrophil and chemotactic markers increase in inflamed tissue of patients and mice receiving immunotherapy. Blockade of IL-6 reduces Th17 and increases Th1 and CD8+ T effector cell density in tumor, mitigates ICB-induced autoimmunity, and potentiates antitumor immunity.

  • 123456 Profile photo of Madelyn

    Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity